Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2022-07-07 , DOI: 10.1002/ejhf.2607
Stuart J Pocock ₁ , João Pedro Ferreira _{2,

3} , Milton Packer _{4,

5} , Faiez Zannad ₃ , Gerasimos Filippatos ₆ , Toru Kondo _{7,

8} , John J V McMurray ₈ , Scott D Solomon ₉ , James L Januzzi ₁₀ , Tomoko Iwata ₁₁ , Afshin Salsali ₁₁ , Javed Butler _{12,

13} , Stefan D Anker ₁₄

Affiliation

Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK.
Department of Surgery and Physiology, Faculty of Medicine, Cardiovascular Research and Development Center, University of Porto, Porto, Portugal.
Inserm, Centre d'Investigations Cliniques Plurithématique 1433, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Université de Lorraine, Nancy, France.
Baylor Heart and Vascular Hospital, Baylor University Medical Center, Dallas, TX, USA.
Imperial College, London, UK.
National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece.
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany.
Baylor Scott and White Research Institute, Dallas, TX, USA.
Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Department of Cardiology, and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.

Biomarker-driven prognostic models incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) in heart failure (HF) with preserved ejection fraction (HFpEF) are lacking. We aimed to generate a biomarker-driven prognostic tool for patients with chronic HFpEF enrolled in EMPEROR-Preserved.

中文翻译：

射血分数保留的慢性心力衰竭的生物标志物驱动的预后模型：EMPEROR–Preserved 试验

在射血分数保留的心力衰竭 (HF) (HFpEF) 中，缺乏结合 N 末端 B 型钠尿肽前体 (NT-proBNP) 和高敏心肌肌钙蛋白 T (hs-cTnT) 的生物标志物驱动的预后模型。我们旨在为参加 EMPEROR-Preserved 的慢性 HFpEF 患者生成一种生物标志物驱动的预后工具。

更新日期：2022-07-07

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11